Patents by Inventor Daniel Rowe

Daniel Rowe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240175876
    Abstract: Disclosed herein are engineered yeast cells, systems, and methods for screening for a ligand that modulates a receptor function and for determining functional consequences of receptor-ligand binding.
    Type: Application
    Filed: November 29, 2023
    Publication date: May 30, 2024
    Inventors: Daniel Isom, Jacob Rowe
  • Publication number: 20240134658
    Abstract: In some aspects, the disclosure is directed to methods and systems for in-application dynamic content loading via a hybrid process, including both local and remote content items, via a content handler intercepting requests in a predetermined uniform resource locator (URL) scheme and redirecting the requests to local storage or a remote content provider, transparently to a browser application or webview of the application, and avoiding restrictions imposed by an operating system of the device. Content may be dynamically updated on the content provider server by developers, and dynamically loaded during execution of the application on client devices, without requiring updates to be provided to an application store or publisher server.
    Type: Application
    Filed: January 5, 2024
    Publication date: April 25, 2024
    Applicant: DK Crown Holdings Inc.
    Inventors: Jon Nguyen, Daniel Kraus, Brian Tourtellott, Jason Rowe
  • Patent number: 9782522
    Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: October 10, 2017
    Assignee: Yale University
    Inventors: Christopher Breuer, Tarek Fahmy, Michael Simons, Pei-Yu Chen, Daniel Rowe Duncan, Joseph Patterson
  • Publication number: 20160310645
    Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.
    Type: Application
    Filed: July 5, 2016
    Publication date: October 27, 2016
    Inventors: Christopher Breuer, Tarek Fahmy, Michael Simons, Pei-Yu Chen, Daniel Rowe Duncan, Joseph Patterson
  • Patent number: 9446175
    Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: September 20, 2016
    Assignee: Yale University
    Inventors: Christopher Breuer, Tarek Fahmy, Michael Simons, Pei-Yu Chen, Daniel Rowe Duncan, Joseph Patterson
  • Publication number: 20140348889
    Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.
    Type: Application
    Filed: June 4, 2012
    Publication date: November 27, 2014
    Applicant: YALE UNIVERSITY
    Inventors: Christopher Breuer, Tarek Fahmy, Michael Simons, Pei-Yu Chen, Daniel Rowe Duncan, Joseph Patterson
  • Patent number: 7437880
    Abstract: A bypass control apparatus is used with a pump pumping a fluid therethrough. A bypass flow line circulates fluid about the pump. A bypass valve is interposed in the bypass flow line and moves between an opened state to permit the fluid to circulate through the bypass flow line back to the pump and a closed state to prevent the fluid from circulating through the bypass flow line. A sensor determines an existing flow-through rate of the fluid flowing through the pump. The controller communicates with the sensor and the bypass valve and moves the bypass valve to the closed state when determined that the existing flow-through rate of the fluid through the pump is at least a predetermined flow-through rate and moves the bypass valve to the opened state when determined that the existing flow-through rate of the fluid through the pump is less than the predetermined flow-through rate.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: October 21, 2008
    Assignee: Refrigeration Valves and Systems Corp.
    Inventors: Daniel Rowe Bansch, Virgil Jordan
  • Publication number: 20050158799
    Abstract: A Toll-IL-1-resistance (TIR) domain-containing adaptor-inducing IFN-? (TRIF)-related adaptor molecule (TRAM) has been identified. TRAM acts specifically in the TLR4 signaling pathway. The invention includes compounds useful for modulating TLR signaling by modulating the effects of TRAM.
    Type: Application
    Filed: October 18, 2004
    Publication date: July 21, 2005
    Inventors: Katherine Fitzgerald, Daniel Rowe, Douglas Golenbock
  • Patent number: 5827228
    Abstract: Trocar assembly devices are disclosed that include an improved elastomeric seal member to maintain sealing engagement during off-centering or radial motion of instruments extending therethrough. The seal members include an inner section and an outer section. The inner section has an opening formed therein to permit an elongate instrument to pass therethrough in sealing engagement therewith. In accordance with certain embodiments, a corrugated portion is formed in the outer section. In accordance with certain embodiments an annular floating ring separates the inner section from the outer section.
    Type: Grant
    Filed: February 16, 1996
    Date of Patent: October 27, 1998
    Assignee: Ethicon, Inc.
    Inventor: C. Daniel Rowe
  • Patent number: 5545142
    Abstract: Trocar assembly devices are disclosed that include an improved elastomeric seal member to maintain sealing engagement during off-centering or radial motion of instruments extending therethrough. The seal members include an inner section and an outer section. The inner section has an opening formed therein to permit an elongate instrument to pass therethrough in sealing engagement therewith. In accordance with certain embodiments, a corrugated portion is formed in the outer section. In accordance with certain embodiments an annular floating ring separates the inner section from the outer section.
    Type: Grant
    Filed: April 12, 1993
    Date of Patent: August 13, 1996
    Assignee: Ethicon, Inc.
    Inventors: Randy R. Stephens, Michael S. Banik, Leslie R. Ashmore, C. Daniel Rowe, George E. Selecman
  • Patent number: 5342315
    Abstract: Trocar assembly embodiments are disclosed that include a trocar tube and a housing defining a chamber adjoining a proximal end portion of the trocar tube. An elastomeric seal member is positioned within the chamber for sealing the chamber as an elongate instrument passes through an opening formed in the seal member. A seal/protector assembly is positioned in the chamber proximally of the seal member in facing relationship to the seal member. The protector assembly includes at least two axially aligned protector members, each of which has an annular collar portion and at least one leaf portion formed integrally with the collar portion so as to form a living hinge portion. The leaf portions define an opening therethrough in axial alignment with the opening in the seal member.
    Type: Grant
    Filed: April 12, 1993
    Date of Patent: August 30, 1994
    Assignee: Ethicon, Inc.
    Inventors: C. Daniel Rowe, Leslie R. Ashmore, Chad C. Carroll, Richard F. Schwemberger, Norman F. Schuler, John M. Collins